tiprankstipranks
Trending News
More News >

Tivic Health Systems Announces Q1 2025 Financial Results

Story Highlights
Tivic Health Systems Announces Q1 2025 Financial Results

Don’t Miss TipRanks’ Half-Year Sale

Tivic Health Systems ( (TIVC) ) has issued an update.

On May 15, 2025, Tivic Health Systems announced its financial results for the first quarter ending March 31, 2025, and highlighted significant strategic shifts, including an expanded clinical pipeline. The company secured a worldwide exclusive licensing agreement for Entolimod and Entolasta, aimed at treating acute radiation syndrome, and engaged with the White House and FDA to explore military applications. Tivic also reported advancements in its non-invasive vagus nerve stimulation program and secured financing agreements to support its transformation strategy. Financially, the company saw a decline in revenue due to reduced sales of its ClearUP device, while maintaining a stable gross margin and operating expenses compared to the previous year.

Spark’s Take on TIVC Stock

According to Spark, TipRanks’ AI Analyst, TIVC is a Neutral.

The overall stock score of 43 reflects Tivic Health Systems’ current financial difficulties, including declining revenues and negative profitability. However, recent strategic initiatives and corporate events provide some optimism for future growth. The stock’s technical indicators and valuation remain weak, necessitating significant improvements in financial performance and market sentiment to enhance stock attractiveness.

To see Spark’s full report on TIVC stock, click here.

More about Tivic Health Systems

Tivic Health Systems, Inc. is a diversified immunotherapeutics company focused on harnessing the immune and autonomic nervous systems to combat disease and restore health. The company develops personalized non-invasive therapeutic devices for vagus nerve stimulation to improve outcomes in inflammatory, neurologic, and cardiac diseases. Tivic Health’s biopharmaceutical program is advancing the toll-like receptor 5 drugs Entolimod and Entolasta, with a focus on treating acute radiation syndrome.

Average Trading Volume: 1,309,386

Technical Sentiment Signal: Sell

Current Market Cap: $3.4M

For detailed information about TIVC stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1